The Food and Drug Administration Monday authorized the emergency use of two new products designed to respond to the COVID-19 ventilator shortage. FDA approved the NASA’s second VITAL ventilator.

Like NASA’s first iteration of the device, VITAL is designed to last three-to-four months using components sourced from outside the current medical device supply chain. Unlike NASA’s first ventilator, VITAL uses an internal compressor as its energy source, rather than wall gas.

Meanwhile, the Fitbit Flow earned an FDA emergency use authorization as an emergency resuscitator. The Fitbit Flow is a continuous respiratory support system that includes an FDA-cleared, Ambu-designed manual resuscitator bag with audible and visual alarms.

By pairing the actuator with a manual resuscitator, health care professionals can use the device to support patients’ respiratory needs when no FDA-cleared clinical ventilators are available.

Related News Articles

Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…
Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
The Department of Health and Human Services Sept. 18 announced it will take new actions to help improve care for individuals with long COVID. They include a…
Headline
The Food and Drug Administration has identified a Class I recall for Mo-Vis BVBA R-net Joysticks due to a firmware error that causes the wheelchair to ignore…
Headline
The Centers for Disease Control and Prevention is predicting a similar combined number of peak hospitalizations from COVID-19, the flu and respiratory…